Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 51803-78-2 Chemical Structure| 51803-78-2

Structure of Nimesulide
CAS No.: 51803-78-2

Chemical Structure| 51803-78-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nimesulide is a COX2 selective inhibitor with IC50 of 26 μM.

Synonyms: R805

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Rybczynska, Malgorzata ; Sikorski, Artur ;

Abstract: The synthesis, spectral properties, thermal anal., structural characterization and in silico prediction of pharmacokinetic parameters of tetramethylammonium (compound 1) and tetraethylammonium (compound 2) salt of nimesulide were described in this article. Both compounds crystallize in the monoclinic P21/n space group, with one tetraalkylammonium cation and one nimesulide anion in the asym. unit and their crystal structures are stabilized by C-H···O hydrogen bonds between ions. Addnl., structures of title compounds are stabilized by π-π interactions (compound 1), or C-H···π interactions (compound 2) between nimesulide anions. The TG and DSC measurements show that compound 1 melts at a temperature higher than nimesulide, whereas the compound 2 melts at a temperature lower than nimesulide. The MALDI-TOF, 1H NMR, 13C NMR and ATR-FTIR analyses confirm the SCXRD study, that in compounds 1 and 2 nimesulide exists in an ionized form. Studies performed by SWISS ADME and ProTOX II tools, predict to be oral bioavailability of both salts obtained, and one of them (compound 1) is predicted to be well-absorbed by digestive system, while both compounds obtained are classified into toxicity class 4.

Purchased from AmBeed:

Alternative Products

Product Details of Nimesulide

CAS No. :51803-78-2
Formula : C13H12N2O5S
M.W : 308.31
SMILES Code : CS(=O)(NC1=CC=C([N+]([O-])=O)C=C1OC2=CC=CC=C2)=O
Synonyms :
R805
MDL No. :MFCD00079470
InChI Key :HYWYRSMBCFDLJT-UHFFFAOYSA-N
Pubchem ID :4495

Safety of Nimesulide

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H361
Precautionary Statements:P501-P270-P202-P201-P264-P280-P308+P313-P301+P310+P330-P405
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • COX-2

    COX-2, IC50:26 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Murine aortic smooth muscle cells 0.1–1 µM 48 hours Nimesulide completely reversed the antimitogenic effect of APOE J Clin Invest. 2004 Feb;113(4):609-18.
Mouse tracheal smooth muscle cells 1 μM 10 minutes To investigate the effect of nimesulide on SLIGRL-NH2-induced tracheal smooth muscle relaxation and PGE2 release, results showed that nimesulide significantly attenuated SLIGRL-NH2-induced relaxation and PGE2 release. Br J Pharmacol. 2001 Jan;132(1):93-100.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
LDL receptor knockout mice High-fat diet-induced atherosclerosis model Drinking water administration 40 mg/liter 18 weeks To evaluate the effect of nimesulide on atherosclerosis. Results showed that nimesulide inhibited COX-2 activity without affecting platelet function and did not significantly alter the progression of atherosclerosis. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3358-63
Mice KrasG12D/+;Trp53−/− non-small-cell lung cancer graft model Intraperitoneal injection 5 mg/kg Single dose To evaluate the therapeutic effect of Nimesulide in combination with Bortezomib on Kras-driven non-small-cell lung cancer, results showed enhanced apoptotic response in tumor cells. J Exp Med. 2018 Dec 3;215(12):3115-3135
Mice Adult mouse brain neurogenesis model Intraperitoneal injection 10 mg/kg Once daily for 5 days Evaluate the effects of nimesulide on brain neurogenesis, results showed significant inhibition of progenitor cell proliferation in the SVZ Br J Pharmacol. 2010 Mar;159(5):1118-25
Mice EC-AMPK transgenic mice Oral gavage 25 mg/kg/day Once daily for 4 weeks Nimesulide significantly ameliorated arterial inflammation, steatohepatitis and hyperlipidaemia in EC-AMPK mice, without altering their blood pressure or clotting. Br J Pharmacol. 2014 Jan;171(2):498-508

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02466581 Rheumatoid Arthritis Phase 4 Recruiting December 2021 Sweden ... More >> Karolinska Institutet Recruiting Stockholm, Sweden, 171 76 Contact: Ronald van Vollenhoven, MD, prof    +46(8)51776077    ronald.van.vollenhoven@ki.se    Contact: Monica Ryden Aulin, PhD    +46(8)51771110    monica.ryden.aulin@ki.se Less <<
NCT02563756 Knee Osteoarthritis Not Applicable Recruiting September 2022 Sweden ... More >> Karolinska University Hospital Recruiting Stockholm, Sweden Contact: Carl Aulin, MD       carl.aulin@karolinska.se    Contact: Nicolas Martinez, MD    +46709900089    nicolas.martinez-carranza@karolinska.se Less <<
NCT03104985 - Completed - -
NCT02575274 Peri-implantitis Phase 2 Phase 3 Unknown July 2016 Brazil ... More >> Federal University of Minas Gerais Belo Horizonte, Minas Gerais, Brazil, 30110031 Less <<
NCT03400462 Temporomandibular Disorder Not Applicable Completed - -
NCT03104985 Trophic Ulcers ... More >> Chronic Venous Insufficiency Less << Not Applicable Completed - Russian Federation ... More >> Tula Municipal Clinical Hospital №2 Tula, Russian Federation, 300002 Less <<
NCT03616574 Advanced or Metastatic Solid T... More >>umors Advanced or Metastatic Colorectal Cancer (mCRC) Less << Phase 1 Not yet recruiting June 2021 -
NCT00932542 Hemorrhoidectomy Phase 2 Phase 3 Unknown November 2012 Brazil ... More >> Clínica Reis Neto Campinas, São Paulo, Brazil, 13010-112 Less <<
NCT03119324 Temporomandibular Joint Disord... More >>ers Less << Not Applicable Completed - -
NCT01670552 Acute and Chronic Inflammation... More >> Dyspepsia Less << Phase 3 Unknown April 2017 Brazil ... More >> Allegisa Recruiting Campinas, São Paulo, Brazil, 13.084-791 Contact: Pedro A. Petersen, MD    +5519 3789-8610    alexandra@grupoinvestiga.com.br    Contact: Alexandra F. Drumont, SC    +5519 3789-8610    alexandra@grupoinvestiga.com.br Less <<
NCT01500577 Breast Cancer Phase 2 Completed - Italy ... More >> European Institute of Oncology Milan, Italy Less <<
NCT02922712 Knee Osteoarthritis Phase 4 Completed - -
NCT01745614 Pain Phase 1 Completed - -
NCT01306708 Adhesive Capsulitis Phase 2 Completed - Brazil ... More >> Universidade do Sul de Santa Catarina Tubarão, Santa Catarina, Brazil, 88704-900 Less <<
NCT02229747 Pharyngitis Phase 4 Completed - -
NCT01257126 Upper Respiratory Tract Infect... More >>ions Less << Phase 4 Withdrawn - -
NCT01609205 Rheumatoid Arthritis Phase 4 Completed - Sweden ... More >> Linköping University Hospital Linköping, Sweden The karolinska Institute Stockholm, Sweden, 171 76 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.24mL

0.65mL

0.32mL

16.22mL

3.24mL

1.62mL

32.43mL

6.49mL

3.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories